NASDAQ · SRRK
Scholar Rock Holding Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SRRK: Nov 10, 2026
Scholar Rock Holding Corporation Common Stock is expected to report earnings on 11/10/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.87. The reported EPS for the same quarter last year was $-0.9.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.87 | $-0.80 | $-0.94 | 8 |
| Dec 2026 | $-0.68 | $0.46 | $-1.00 | 7 |
| Mar 2027 | $-0.85 | $-0.74 | $-0.98 | 4 |
| Jun 2027 | $-0.78 | $-0.68 | $-0.87 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · MarketBeat · The Motley Fool- BNK Invest · Oct 28, 10:47 AM EDTWednesday 10/28 Insider Buying Report: LRN, SRRKBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
- RTTNews · Oct 16, 3:02 PM EDTFDA Drug Approvals In September 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.With the month yielding a mix of new therapies and expanded treatment
- RTTNews · Oct 8, 10:02 AM EDTScholar Rock Revives European Filing For SMA Therapy After U.S. Approval(RTTNews) – Scholar Rock (SRRK) has resubmitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA), a rare genetic neuromuscular disease t
- RTTNews · Oct 8, 8:27 AM EDTScholar Rock Resubmits Marketing Authorisation Application For Apitegromab(RTTNews) – Scholar Rock (SRRK) has resubmitted the Marketing Authorisation Application for apitegromab for the treatment of children and adults with spinal muscular atrophy to the European Medicines Agency. The resubmitted apitegromab MAA includes Scholar Rock's alternate fill-f
- RTTNews · Sep 18, 10:44 AM EDTWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) – Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
- RTTNews · Sep 12, 2:02 AM EDTScholar Rock's ISEMBYLD Wins FDA Approval As First Muscle-Targeted Therapy For SMA(RTTNews) – Scholar Rock (SRRK) announced that the U.S. Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SM
- RTTNews · Sep 2, 8:31 AM EDTScholar Rock: FDA Grants Fast Track And Orphan Drug Designations To Apitegromab(RTTNews) – Scholar Rock (SRRK) announced that the FDA has granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with Facioscapulohumeral Muscular Dystrophy. Also, Scholar Rock announced that participant dosing is underway in the Phase
- RTTNews · Aug 26, 11:11 AM EDTBiotech Stocks Facing FDA Decision In September 2026(RTTNews) – As September ushers in the first hints of autumn, it also brings a packed FDA regulatory calendar.
- BNK Invest · Aug 21, 10:07 AM EDTSee Which Recent 13F Filers Hold SRRKAt Holdings Channel, we have reviewed the latest batch of the 56 most recent 13F filings for the 06/30/2026 reporting period, and noticed that Scholar Rock Holding Corp (Symbol: SRRK) was held by 28 of these funds. When hedge fund managers appear to be thinking alike, we find it
- MarketBeat · Aug 17, 7:03 PM EDTScholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab3 Beaten-Down Stocks With Rebound Potential This Earnings SeasonScholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitt
- The Motley Fool · Aug 13, 9:29 AM EDTScholar Rock (SRRK) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 7, 7:20 PM EDTScholar Rock Says FDA Review Of Apitegromab BLA Continues; Approval Decision Expected By Sept. 30(RTTNews) – Scholar Rock Holding Corp. (SRRK) said Friday the U.S. Food and Drug Administration will continue reviewing the Biologics License Application, or BLA, for apitegromab using the company's second fill-finish manufacturing facility, keeping the application on track for a
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Scholar Rock Holding Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.